Sara Shalin
Concepts (437)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 36 | 2025 | 500 | 9.580 |
Why?
| | Skin Diseases | 7 | 2022 | 117 | 3.720 |
Why?
| | Melanoma | 16 | 2024 | 277 | 3.690 |
Why?
| | Dermatology | 9 | 2024 | 54 | 3.070 |
Why?
| | Skin | 12 | 2024 | 419 | 2.940 |
Why?
| | Carcinoma, Basal Cell | 6 | 2025 | 39 | 2.520 |
Why?
| | Immunohistochemistry | 19 | 2025 | 975 | 2.010 |
Why?
| | Biopsy | 21 | 2025 | 600 | 1.890 |
Why?
| | Nevus, Pigmented | 3 | 2024 | 34 | 1.790 |
Why?
| | Sebaceous Gland Neoplasms | 5 | 2022 | 16 | 1.680 |
Why?
| | Staining and Labeling | 3 | 2021 | 94 | 1.490 |
Why?
| | Adenocarcinoma, Sebaceous | 3 | 2022 | 7 | 1.450 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2025 | 44 | 1.440 |
Why?
| | Humans | 88 | 2025 | 53230 | 1.360 |
Why?
| | Carcinoma, Merkel Cell | 3 | 2025 | 41 | 1.350 |
Why?
| | Nevus, Blue | 2 | 2021 | 11 | 1.270 |
Why?
| | Melanocytes | 3 | 2021 | 38 | 1.260 |
Why?
| | Female | 49 | 2025 | 28782 | 1.190 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 75 | 1.180 |
Why?
| | Dermatitis | 2 | 2022 | 36 | 1.160 |
Why?
| | Erythema Multiforme | 2 | 2020 | 11 | 1.100 |
Why?
| | Middle Aged | 33 | 2025 | 13419 | 1.080 |
Why?
| | Diagnosis, Differential | 15 | 2025 | 1038 | 1.070 |
Why?
| | Aged | 29 | 2025 | 10429 | 1.040 |
Why?
| | Vasculitis | 2 | 2024 | 28 | 0.980 |
Why?
| | Vulvar Neoplasms | 3 | 2022 | 61 | 0.980 |
Why?
| | Aged, 80 and over | 18 | 2024 | 3494 | 0.980 |
Why?
| | Alopecia | 2 | 2024 | 38 | 0.940 |
Why?
| | Herpes Simplex | 2 | 2022 | 25 | 0.910 |
Why?
| | Urticaria | 1 | 2025 | 19 | 0.900 |
Why?
| | Sebaceous Glands | 2 | 2024 | 13 | 0.880 |
Why?
| | Skin Diseases, Vascular | 1 | 2024 | 8 | 0.870 |
Why?
| | Adult | 25 | 2025 | 14534 | 0.860 |
Why?
| | Neoplasm Staging | 2 | 2024 | 774 | 0.860 |
Why?
| | Incidental Findings | 1 | 2024 | 43 | 0.860 |
Why?
| | Dermatitis, Seborrheic | 1 | 2024 | 4 | 0.850 |
Why?
| | Sweat Gland Neoplasms | 3 | 2024 | 22 | 0.850 |
Why?
| | Atrophy | 1 | 2024 | 48 | 0.840 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2024 | 119 | 0.820 |
Why?
| | Plasma Cells | 1 | 2025 | 234 | 0.810 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 3 | 2018 | 15 | 0.800 |
Why?
| | Fibroma | 3 | 2025 | 41 | 0.800 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 177 | 0.800 |
Why?
| | Hyperoxaluria | 1 | 2022 | 3 | 0.780 |
Why?
| | Male | 34 | 2025 | 27435 | 0.780 |
Why?
| | Urolithiasis | 1 | 2022 | 4 | 0.770 |
Why?
| | Hyperoxaluria, Primary | 1 | 2022 | 3 | 0.770 |
Why?
| | Graft vs Host Disease | 2 | 2020 | 93 | 0.760 |
Why?
| | Adenoma | 2 | 2017 | 114 | 0.760 |
Why?
| | Pathology | 2 | 2020 | 37 | 0.760 |
Why?
| | Epidermal Cyst | 1 | 2022 | 12 | 0.740 |
Why?
| | Granuloma | 2 | 2020 | 46 | 0.740 |
Why?
| | Carcinoma in Situ | 1 | 2022 | 72 | 0.730 |
Why?
| | Protein Kinases | 2 | 2016 | 72 | 0.720 |
Why?
| | Muscle, Smooth | 1 | 2021 | 62 | 0.710 |
Why?
| | Fungi | 1 | 2021 | 51 | 0.690 |
Why?
| | Elastic Tissue | 2 | 2020 | 10 | 0.690 |
Why?
| | Artifacts | 1 | 2021 | 55 | 0.680 |
Why?
| | Epidermodysplasia Verruciformis | 1 | 2020 | 2 | 0.680 |
Why?
| | Foreign Bodies | 1 | 2021 | 66 | 0.680 |
Why?
| | Scabies | 2 | 2025 | 6 | 0.670 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2020 | 2 | 0.670 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 2020 | 14 | 0.670 |
Why?
| | Methenamine | 1 | 2020 | 1 | 0.660 |
Why?
| | Periodic Acid-Schiff Reaction | 1 | 2020 | 2 | 0.660 |
Why?
| | Lichenoid Eruptions | 1 | 2020 | 3 | 0.660 |
Why?
| | Vulvar Diseases | 1 | 2020 | 7 | 0.660 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 62 | 0.660 |
Why?
| | Kidney Failure, Chronic | 1 | 2022 | 210 | 0.650 |
Why?
| | Lymphatic Metastasis | 2 | 2020 | 211 | 0.650 |
Why?
| | Genitalia | 1 | 2020 | 10 | 0.650 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2020 | 51 | 0.650 |
Why?
| | Lichen Sclerosus et Atrophicus | 1 | 2020 | 7 | 0.650 |
Why?
| | Syphilis | 1 | 2020 | 21 | 0.650 |
Why?
| | Gynecology | 1 | 2020 | 52 | 0.640 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2020 | 67 | 0.630 |
Why?
| | Pseudoxanthoma Elasticum | 1 | 2019 | 4 | 0.610 |
Why?
| | Young Adult | 11 | 2025 | 4511 | 0.610 |
Why?
| | Pathology, Surgical | 1 | 2019 | 23 | 0.590 |
Why?
| | Pathology, Clinical | 4 | 2021 | 25 | 0.580 |
Why?
| | Telangiectasis | 1 | 2018 | 3 | 0.570 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.560 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2024 | 332 | 0.560 |
Why?
| | Carcinoma, Large Cell | 1 | 2017 | 17 | 0.540 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2017 | 27 | 0.540 |
Why?
| | Laryngeal Neoplasms | 1 | 2017 | 44 | 0.530 |
Why?
| | Hidrocystoma | 1 | 2017 | 5 | 0.530 |
Why?
| | Calcium Oxalate | 1 | 2017 | 7 | 0.530 |
Why?
| | Apocrine Glands | 1 | 2017 | 8 | 0.530 |
Why?
| | Inflammation | 2 | 2020 | 652 | 0.510 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2020 | 228 | 0.480 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 59 | 0.480 |
Why?
| | Transcription Factors | 2 | 2021 | 571 | 0.470 |
Why?
| | Sarcoptes scabiei | 1 | 2015 | 2 | 0.460 |
Why?
| | Brain Neoplasms | 2 | 2020 | 319 | 0.450 |
Why?
| | Genital Diseases, Male | 1 | 2015 | 18 | 0.450 |
Why?
| | Lymphangioma | 1 | 2014 | 9 | 0.450 |
Why?
| | Histiocytosis, Sinus | 1 | 2015 | 14 | 0.440 |
Why?
| | Scrotum | 1 | 2015 | 31 | 0.440 |
Why?
| | Arm | 1 | 2014 | 47 | 0.420 |
Why?
| | Adolescent | 9 | 2025 | 6907 | 0.410 |
Why?
| | Acanthoma | 1 | 2013 | 2 | 0.410 |
Why?
| | Fibroadenoma | 1 | 2013 | 7 | 0.410 |
Why?
| | Eccrine Glands | 1 | 2013 | 11 | 0.410 |
Why?
| | Nuclear Proteins | 1 | 2014 | 250 | 0.390 |
Why?
| | Leuprolide | 1 | 2012 | 3 | 0.380 |
Why?
| | Mucinosis, Follicular | 1 | 2012 | 3 | 0.380 |
Why?
| | Drug Eruptions | 1 | 2012 | 14 | 0.380 |
Why?
| | Endometriosis | 1 | 2012 | 15 | 0.380 |
Why?
| | Mycosis Fungoides | 1 | 2012 | 26 | 0.370 |
Why?
| | Cicatrix | 1 | 2012 | 43 | 0.370 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2012 | 35 | 0.370 |
Why?
| | Thrombosis | 1 | 2015 | 250 | 0.370 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 56 | 0.360 |
Why?
| | Dermis | 2 | 2021 | 19 | 0.350 |
Why?
| | Social Media | 3 | 2018 | 125 | 0.340 |
Why?
| | Histones | 3 | 2020 | 318 | 0.340 |
Why?
| | Cesarean Section | 1 | 2012 | 158 | 0.340 |
Why?
| | Vulva | 2 | 2020 | 18 | 0.330 |
Why?
| | Mucous Membrane | 2 | 2020 | 32 | 0.330 |
Why?
| | Muir-Torre Syndrome | 1 | 2010 | 1 | 0.320 |
Why?
| | Hippocampus | 3 | 2006 | 195 | 0.310 |
Why?
| | Neutrophils | 2 | 2025 | 153 | 0.310 |
Why?
| | Gene Rearrangement | 2 | 2021 | 76 | 0.310 |
Why?
| | Mutation | 4 | 2024 | 1337 | 0.280 |
Why?
| | Epithelioid Cells | 2 | 2020 | 12 | 0.280 |
Why?
| | Up-Regulation | 3 | 2020 | 456 | 0.270 |
Why?
| | Retrospective Studies | 5 | 2025 | 6819 | 0.260 |
Why?
| | Dermatomycoses | 2 | 2016 | 17 | 0.250 |
Why?
| | Factor XIIIa | 2 | 2016 | 10 | 0.250 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2016 | 208 | 0.240 |
Why?
| | Mutation, Missense | 3 | 2020 | 110 | 0.240 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 44 | 0.240 |
Why?
| | Memory | 1 | 2006 | 97 | 0.230 |
Why?
| | Antifungal Agents | 3 | 2016 | 350 | 0.230 |
Why?
| | Memory Disorders | 1 | 2006 | 47 | 0.230 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 127 | 0.230 |
Why?
| | Postoperative Complications | 1 | 2012 | 1099 | 0.230 |
Why?
| | Mast Cells | 1 | 2025 | 56 | 0.220 |
Why?
| | Signal Transduction | 2 | 2016 | 1748 | 0.220 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2024 | 3 | 0.220 |
Why?
| | Neurons | 2 | 2006 | 394 | 0.220 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2024 | 25 | 0.220 |
Why?
| | SOXE Transcription Factors | 2 | 2021 | 4 | 0.210 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 47 | 0.210 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2019 | 610 | 0.210 |
Why?
| | MART-1 Antigen | 2 | 2021 | 12 | 0.210 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 867 | 0.210 |
Why?
| | Chickenpox | 1 | 2024 | 17 | 0.210 |
Why?
| | Nevus | 1 | 2024 | 16 | 0.210 |
Why?
| | Lymphoma | 1 | 2024 | 71 | 0.210 |
Why?
| | Carcinoma | 1 | 2024 | 136 | 0.200 |
Why?
| | Disease Outbreaks | 1 | 2024 | 120 | 0.200 |
Why?
| | Fear | 1 | 2004 | 85 | 0.200 |
Why?
| | Oxalates | 1 | 2022 | 10 | 0.190 |
Why?
| | Angioedema | 1 | 2022 | 11 | 0.190 |
Why?
| | Demography | 1 | 2022 | 91 | 0.190 |
Why?
| | Kidney Transplantation | 1 | 2025 | 203 | 0.190 |
Why?
| | Sarcoidosis | 1 | 2022 | 44 | 0.180 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2022 | 8 | 0.180 |
Why?
| | Prednisone | 1 | 2022 | 101 | 0.180 |
Why?
| | Foot | 1 | 2022 | 41 | 0.180 |
Why?
| | Plant Structures | 1 | 2021 | 5 | 0.180 |
Why?
| | Cotton Fiber | 1 | 2021 | 4 | 0.180 |
Why?
| | Herpesvirus 2, Human | 1 | 2021 | 4 | 0.180 |
Why?
| | Lymphokines | 1 | 2021 | 20 | 0.180 |
Why?
| | Paper | 1 | 2021 | 16 | 0.180 |
Why?
| | Herpesvirus 1, Human | 1 | 2021 | 16 | 0.180 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2021 | 25 | 0.180 |
Why?
| | Histocytochemistry | 1 | 2021 | 44 | 0.180 |
Why?
| | Dermatofibrosarcoma | 1 | 2021 | 9 | 0.180 |
Why?
| | Herpesvirus 3, Human | 1 | 2021 | 32 | 0.180 |
Why?
| | Sutures | 1 | 2021 | 36 | 0.180 |
Why?
| | Hyperplasia | 1 | 2021 | 98 | 0.180 |
Why?
| | Coloring Agents | 1 | 2021 | 65 | 0.170 |
Why?
| | Protein Processing, Post-Translational | 2 | 2020 | 149 | 0.170 |
Why?
| | Animals | 10 | 2021 | 13526 | 0.170 |
Why?
| | Stromal Cells | 1 | 2021 | 77 | 0.170 |
Why?
| | Cadherins | 2 | 2019 | 62 | 0.170 |
Why?
| | Chromones | 1 | 2021 | 16 | 0.170 |
Why?
| | Lost to Follow-Up | 1 | 2020 | 10 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 868 | 0.170 |
Why?
| | Oncogene Fusion | 1 | 2020 | 4 | 0.170 |
Why?
| | Leprosy, Multibacillary | 1 | 2020 | 4 | 0.170 |
Why?
| | Armadillos | 1 | 2020 | 5 | 0.170 |
Why?
| | Research Report | 1 | 2020 | 19 | 0.170 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2021 | 24 | 0.170 |
Why?
| | Morpholines | 1 | 2021 | 64 | 0.170 |
Why?
| | Skin Transplantation | 1 | 2021 | 43 | 0.170 |
Why?
| | S100 Proteins | 2 | 2021 | 33 | 0.170 |
Why?
| | Histiocytes | 1 | 2020 | 10 | 0.160 |
Why?
| | Neoplasms, Fibrous Tissue | 1 | 2020 | 2 | 0.160 |
Why?
| | Papillomaviridae | 1 | 2020 | 104 | 0.160 |
Why?
| | Graft Survival | 1 | 2021 | 157 | 0.160 |
Why?
| | Germ Cells | 1 | 2020 | 14 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 89 | 0.160 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2020 | 58 | 0.160 |
Why?
| | Phagocytosis | 1 | 2020 | 59 | 0.160 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2020 | 11 | 0.160 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 72 | 0.160 |
Why?
| | Immunotherapy | 2 | 2019 | 266 | 0.160 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2020 | 88 | 0.160 |
Why?
| | Graft Rejection | 1 | 2021 | 166 | 0.160 |
Why?
| | Adenocarcinoma | 1 | 2024 | 405 | 0.160 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2021 | 140 | 0.160 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 78 | 0.160 |
Why?
| | Consensus | 1 | 2020 | 206 | 0.150 |
Why?
| | Elastin | 1 | 2019 | 24 | 0.150 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2019 | 33 | 0.150 |
Why?
| | Integrin alpha Chains | 1 | 2019 | 12 | 0.150 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 32 | 0.150 |
Why?
| | Disease Progression | 3 | 2020 | 880 | 0.150 |
Why?
| | Melanoma, Experimental | 1 | 2019 | 34 | 0.140 |
Why?
| | Child | 4 | 2022 | 7379 | 0.140 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 423 | 0.140 |
Why?
| | Arteriovenous Malformations | 1 | 2019 | 75 | 0.140 |
Why?
| | Collagen | 1 | 2019 | 215 | 0.140 |
Why?
| | Acute Disease | 1 | 2019 | 393 | 0.140 |
Why?
| | Cricoid Cartilage | 1 | 2017 | 10 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 34 | 0.130 |
Why?
| | Antigens, CD | 1 | 2019 | 217 | 0.130 |
Why?
| | Dilatation | 1 | 2017 | 28 | 0.130 |
Why?
| | Tumor Burden | 1 | 2017 | 132 | 0.130 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2018 | 83 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 502 | 0.130 |
Why?
| | Parvoviridae Infections | 1 | 2017 | 19 | 0.130 |
Why?
| | Parvovirus B19, Human | 1 | 2017 | 16 | 0.130 |
Why?
| | Immunologic Surveillance | 1 | 2017 | 10 | 0.130 |
Why?
| | Connective Tissue Diseases | 1 | 2017 | 20 | 0.130 |
Why?
| | Tumor Escape | 1 | 2017 | 18 | 0.130 |
Why?
| | CTLA-4 Antigen | 1 | 2017 | 32 | 0.130 |
Why?
| | Histone Code | 1 | 2017 | 32 | 0.130 |
Why?
| | Rhizopus | 1 | 2016 | 4 | 0.130 |
Why?
| | Trachea | 1 | 2017 | 55 | 0.130 |
Why?
| | Sarcoma | 1 | 2018 | 72 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 46 | 0.130 |
Why?
| | RNA, Fungal | 1 | 2016 | 18 | 0.130 |
Why?
| | Mucormycosis | 1 | 2016 | 28 | 0.130 |
Why?
| | Connexins | 1 | 2016 | 24 | 0.130 |
Why?
| | Splenomegaly | 1 | 2016 | 12 | 0.130 |
Why?
| | Ascomycota | 1 | 2016 | 8 | 0.130 |
Why?
| | Angiomyoma | 1 | 2016 | 5 | 0.130 |
Why?
| | Apoptosis | 3 | 2019 | 1139 | 0.120 |
Why?
| | Mice | 6 | 2021 | 5982 | 0.120 |
Why?
| | Osteosarcoma | 1 | 2016 | 44 | 0.120 |
Why?
| | Infant | 2 | 2015 | 3805 | 0.120 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2016 | 78 | 0.120 |
Why?
| | Recurrence | 2 | 2015 | 694 | 0.120 |
Why?
| | Human Growth Hormone | 1 | 2016 | 49 | 0.120 |
Why?
| | Candidiasis | 1 | 2016 | 114 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2016 | 133 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 187 | 0.120 |
Why?
| | Adipocytes | 1 | 2016 | 131 | 0.120 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 76 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2019 | 645 | 0.110 |
Why?
| | Avoidance Learning | 2 | 2006 | 17 | 0.110 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2015 | 16 | 0.110 |
Why?
| | Fibrin | 1 | 2015 | 10 | 0.110 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2015 | 18 | 0.110 |
Why?
| | Lysine | 1 | 2015 | 91 | 0.110 |
Why?
| | Facial Neoplasms | 1 | 2015 | 22 | 0.110 |
Why?
| | WT1 Proteins | 1 | 2014 | 4 | 0.110 |
Why?
| | Immunocompromised Host | 3 | 2025 | 124 | 0.110 |
Why?
| | Pigmentation Disorders | 1 | 2014 | 6 | 0.110 |
Why?
| | Carcinosarcoma | 1 | 2015 | 18 | 0.110 |
Why?
| | Purpura | 1 | 2014 | 7 | 0.110 |
Why?
| | Eosinophils | 1 | 2015 | 40 | 0.110 |
Why?
| | Keratin-20 | 1 | 2014 | 7 | 0.110 |
Why?
| | Hemangiosarcoma | 1 | 2014 | 18 | 0.110 |
Why?
| | Herpes Zoster | 1 | 2014 | 16 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2016 | 134 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2016 | 124 | 0.110 |
Why?
| | Loss of Heterozygosity | 1 | 2015 | 78 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2018 | 325 | 0.110 |
Why?
| | Prospective Studies | 1 | 2020 | 2411 | 0.110 |
Why?
| | United States | 2 | 2022 | 5409 | 0.110 |
Why?
| | Churg-Strauss Syndrome | 1 | 2014 | 3 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 117 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 130 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 350 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2015 | 294 | 0.110 |
Why?
| | Lymphocytes | 1 | 2015 | 146 | 0.110 |
Why?
| | Antigens, CD34 | 1 | 2014 | 76 | 0.110 |
Why?
| | Exanthema | 1 | 2014 | 33 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 330 | 0.100 |
Why?
| | Eosinophilia | 1 | 2014 | 34 | 0.100 |
Why?
| | Sarcoma, Kaposi | 1 | 2014 | 77 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 238 | 0.100 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 297 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 477 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 3 | 2020 | 487 | 0.100 |
Why?
| | Head and Neck Neoplasms | 1 | 2016 | 291 | 0.100 |
Why?
| | Prognosis | 4 | 2019 | 2118 | 0.090 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2013 | 141 | 0.090 |
Why?
| | DNA Mismatch Repair | 1 | 2012 | 18 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2021 | 5595 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 934 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2014 | 681 | 0.090 |
Why?
| | Multiple Myeloma | 2 | 2016 | 3082 | 0.090 |
Why?
| | Asthma | 1 | 2014 | 319 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 579 | 0.080 |
Why?
| | Fatal Outcome | 2 | 2022 | 193 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 145 | 0.070 |
Why?
| | Phorbol Esters | 1 | 2006 | 4 | 0.060 |
Why?
| | Theta Rhythm | 1 | 2006 | 7 | 0.060 |
Why?
| | Association Learning | 1 | 2006 | 11 | 0.060 |
Why?
| | Amphotericin B | 2 | 2016 | 105 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 69 | 0.060 |
Why?
| | Isoproterenol | 1 | 2006 | 55 | 0.060 |
Why?
| | Maze Learning | 1 | 2006 | 35 | 0.060 |
Why?
| | Adrenergic beta-Agonists | 1 | 2006 | 39 | 0.060 |
Why?
| | Child, Preschool | 1 | 2015 | 4162 | 0.060 |
Why?
| | Protein Kinase C | 1 | 2006 | 68 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 84 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 237 | 0.060 |
Why?
| | Fingers | 1 | 2025 | 34 | 0.060 |
Why?
| | Permethrin | 1 | 2025 | 5 | 0.060 |
Why?
| | Ivermectin | 1 | 2025 | 10 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2019 | 1031 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2017 | 321 | 0.060 |
Why?
| | Intellectual Disability | 1 | 2006 | 129 | 0.050 |
Why?
| | Time Factors | 2 | 2016 | 2991 | 0.050 |
Why?
| | Superior Cervical Ganglion | 1 | 2004 | 5 | 0.050 |
Why?
| | Disease Notification | 1 | 2024 | 9 | 0.050 |
Why?
| | Sensory Thresholds | 1 | 2004 | 15 | 0.050 |
Why?
| | Blotting, Southern | 1 | 2004 | 40 | 0.050 |
Why?
| | Nerve Growth Factor | 1 | 2004 | 13 | 0.050 |
Why?
| | Exploratory Behavior | 1 | 2004 | 24 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 46 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2004 | 48 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2004 | 85 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 69 | 0.050 |
Why?
| | Shock | 1 | 2004 | 33 | 0.050 |
Why?
| | Physician's Role | 1 | 2024 | 49 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 152 | 0.050 |
Why?
| | Brain | 2 | 2019 | 1350 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2004 | 126 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 357 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 253 | 0.050 |
Why?
| | Behavior, Animal | 1 | 2004 | 187 | 0.050 |
Why?
| | Blotting, Western | 1 | 2004 | 587 | 0.050 |
Why?
| | Motor Activity | 1 | 2004 | 227 | 0.050 |
Why?
| | Eyelids | 1 | 2022 | 27 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2004 | 561 | 0.050 |
Why?
| | Desmin | 1 | 2022 | 7 | 0.050 |
Why?
| | Edema | 1 | 2022 | 64 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2318 | 0.050 |
Why?
| | Gene Expression | 1 | 2004 | 618 | 0.040 |
Why?
| | gp100 Melanoma Antigen | 1 | 2021 | 8 | 0.040 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2021 | 3 | 0.040 |
Why?
| | DNA, Viral | 1 | 2021 | 136 | 0.040 |
Why?
| | Mycobacterium leprae | 1 | 2020 | 6 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 266 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1367 | 0.040 |
Why?
| | Soil Microbiology | 1 | 2020 | 20 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2004 | 1133 | 0.040 |
Why?
| | Societies, Medical | 1 | 2021 | 207 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2004 | 1569 | 0.040 |
Why?
| | Retinoblastoma Protein | 1 | 2020 | 19 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 14 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 1544 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 310 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2021 | 275 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 135 | 0.040 |
Why?
| | Ulcer | 1 | 2020 | 24 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 65 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2021 | 179 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 67 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 62 | 0.040 |
Why?
| | Malpractice | 1 | 2019 | 16 | 0.040 |
Why?
| | Linear Models | 1 | 2020 | 287 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2021 | 400 | 0.040 |
Why?
| | Microcirculation | 1 | 2019 | 63 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 68 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 445 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2020 | 598 | 0.040 |
Why?
| | Fibrosis | 1 | 2019 | 198 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 659 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 441 | 0.030 |
Why?
| | Rats | 1 | 2004 | 3162 | 0.030 |
Why?
| | Rare Diseases | 1 | 2018 | 47 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 367 | 0.030 |
Why?
| | Larynx | 1 | 2017 | 30 | 0.030 |
Why?
| | Cadaver | 1 | 2017 | 90 | 0.030 |
Why?
| | Pressure | 1 | 2017 | 102 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2018 | 120 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 36 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 533 | 0.030 |
Why?
| | Forearm | 1 | 2016 | 30 | 0.030 |
Why?
| | Debridement | 1 | 2016 | 49 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 726 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 466 | 0.030 |
Why?
| | Toes | 1 | 2016 | 15 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2016 | 36 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 56 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 163 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 274 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2016 | 65 | 0.030 |
Why?
| | Family | 1 | 2018 | 179 | 0.030 |
Why?
| | Treatment Refusal | 1 | 2016 | 35 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2016 | 65 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 122 | 0.030 |
Why?
| | Abscess | 1 | 2016 | 43 | 0.030 |
Why?
| | Triazoles | 1 | 2016 | 114 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 181 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2016 | 181 | 0.030 |
Why?
| | Cell Movement | 1 | 2017 | 279 | 0.030 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 46 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 1517 | 0.030 |
Why?
| | Epigenomics | 1 | 2016 | 76 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 452 | 0.030 |
Why?
| | Methylation | 1 | 2015 | 127 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 1925 | 0.030 |
Why?
| | Proteome | 1 | 2017 | 177 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 128 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2015 | 38 | 0.030 |
Why?
| | Scalp | 1 | 2015 | 44 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2016 | 488 | 0.030 |
Why?
| | Bone Marrow | 1 | 2016 | 359 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2014 | 52 | 0.030 |
Why?
| | Arkansas | 1 | 2020 | 2068 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 179 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2014 | 89 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 476 | 0.030 |
Why?
| | Lipodystrophy | 1 | 2013 | 9 | 0.030 |
Why?
| | Heterozygote | 1 | 2013 | 89 | 0.020 |
Why?
| | Incidence | 1 | 2016 | 1085 | 0.020 |
Why?
| | Muscular Atrophy | 1 | 2013 | 73 | 0.020 |
Why?
| | Syndrome | 1 | 2013 | 248 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 647 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 412 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 1368 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 1470 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 1049 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 1583 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 1180 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1232 | 0.020 |
Why?
|
|
Shalin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|